# Literature Review: Glioblastoma

*Auto-generated on February 14, 2026 using arXiv and Perplexity AI.*

---

# Literature Review: Glioblastoma – Insights from Recent arXiv Research

## 1. Introduction to Glioblastoma (Epidemiology, Significance)

Glioblastoma (GBM), also known as glioblastoma multiforme, is the most common and aggressive malignant primary brain tumor in adults, characterized by rapid progression, high invasiveness, and poor prognosis.[6] It manifests as heterogeneous necrotic masses with irregular peripheral enhancement and surrounding vasogenic edema, leading to a median survival of approximately 12 months with optimal therapy (surgical resection, radiotherapy, and chemotherapy) and about 4 months without treatment.[6] Globally, glioblastomas contribute significantly to brain tumor mortality, with an estimated 200,000 annual deaths worldwide, underscoring their clinical urgency.[6]

Epidemiologically, GBM affects adults predominantly, with cases rising in incidence and prevalence, though exact figures vary due to detection challenges.[2] Standard care involves maximal resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ), yet recurrence is common due to microscopic residual foci and treatment resistance.[1][2][7] The tumor's heterogeneity in microstructure, vasculature, and genetics drives regional diversity in treatment response, making early detection, precise segmentation, and personalized prognostication critical. Recent advances emphasize molecular subtyping and imaging biomarkers for improved outcomes, as survival rates remain dismal, with few patients surviving beyond 2.5 years.[1]

## 2. Molecular and Genetic Landscape of Glioblastoma

The molecular landscape of GBM is marked by profound intratumoral heterogeneity, influencing histology, imaging characteristics, and therapeutic response.[3] Key features include gene expression alterations that define molecular subtypes, correlated with enhancement, edema, and survival via radiomics from tumor subregions. Radiogenomic analyses link MRI-derived intensity, volume, and texture features to these subtypes, enabling non-invasive prediction.[3]

MGMT promoter methylation status is a pivotal biomarker, predicting TMZ response; hypomethylation confers resistance, while methylation enhances efficacy. Studies employ explainable deep radiogenomic imaging to predict MGMT status without invasive biopsies, addressing heterogeneity risks. Mutated driver pathways exhibit distinct topologies across cancers, with GBM showing unique pathway interconnections compared to others like acute myeloid leukemia. Multimodal approaches, integrating MRI and histopathology, preserve structural information for subtype classification, aiding targeted therapy selection.[3]

Radiomics and deep learning further delineate genomic underpinnings, associating imaging signatures with immune apparatus and molecular predictors for prognostication.[4] Tumor growth models reveal infiltration beyond visible boundaries, complicating delineation.

## 3. Key Protein Targets for Treatment

Targeting specific proteins in GBM is rationalized by their roles in proliferation, resistance, and homeostasis. Below are key targets highlighted in the literature, with biological rationales:

- **O6-methylguanine-DNA methyltransferase (MGMT)**: MGMT repairs TMZ-induced DNA damage by removing alkyl groups from guanine, conferring chemoresistance in unmethylated promoters. Targeting or predicting methylation status via radiogenomics enables patient stratification for TMZ benefit, improving survival in responders.

- **Ion channels and homeostasis regulators (Ca²⁺ and K⁺)**: Low-intensity electric stimulation disrupts Ca²⁺ and K⁺ homeostasis, reducing multidrug resistance and inducing anti-proliferative effects. Piezoelectric barium titanate nanostimulators exploit this by generating local fields post-surgery, targeting residual foci to prevent recurrence.[7]

- **Immune checkpoint and tumor-host immune proteins**: Radiogenomic biomarkers identify imaging signatures of the tumor immune microenvironment, stratifying patients for immunotherapy. These targets address immune evasion, with preoperative MRI predicting response to enable neo-adjuvant personalization.[4]

- **Driver pathway proteins**: Mutated drivers in interconnected pathways (e.g., growth signaling, apoptosis regulators) sustain GBM aggression. Topology mapping reveals GBM-specific vulnerabilities for multi-pathway inhibition, differing from other cancers.

These targets leverage GBM's genetic alterations for precision approaches, overcoming heterogeneity.

## 4. Current Therapeutic Strategies and Clinical Relevance

Standard therapy combines maximal safe resection, radiotherapy, and TMZ, yet outcomes are limited by infiltration, resistance, and recurrence.[1][2][6] Mathematical models simulate heterogeneous growth and treatment responses, optimizing resection plus concurrent chemo-radiotherapy and adjuvant TMZ for personalized planning.[2]

Emerging strategies integrate AI and imaging:

- **Tumor Treating Fields (TTFields)**: Electric field therapy disrupts mitosis; electrode array positioning, optimized via patient-specific modeling, maximizes field intensity at tumor sites.[5]

- **Machine learning for monitoring and prediction**: ML biomarkers assess treatment response post-standard care, while multi-parametric MRI predicts survival across treatments (e.g., resection + RT + TMZ vs. alternatives).[1] Unsupervised learning partitions intra-tumor regions for survival forecasting.

- **Radiomics and deep learning**: Enhance prognostication beyond clinical/molecular data, predicting subtypes, MGMT status, and outcomes (≤6 vs. >6 months survival).[3] AI aids segmentation and planning accuracy.[6]

- **Novel modalities**: Piezoelectric nanostimulators reduce resistance; radiogenomics guides immunotherapy.[4][7]

Clinical relevance lies in personalization: preoperative MRI-based survival inference compares treatments, while sheaf networks and Bayesian optimization improve subtype prediction and partitioning.[3] Multicenter validation confirms radiomics' added value. Challenges persist in robustness and interpretability, but these approaches promise stratified trials and reduced invasiveness.[1]

## 5. References

[1] Booth, T., et al. "Machine Learning and Glioblastoma: Treatment Response Monitoring Biomarkers in 2021." arXiv:2104.08072v1 (2021).

[2] Samadifam, F., & Ghafourian, E. "Mathematical modeling of the treatment response of resection plus combined chemotherapy and different types of radiation therapy in a glioblastoma patient." arXiv:2308.07976v2 (2023).

[3] Idrissova, S., & Rekik, I. "Multimodal Sheaf-based Network for Glioblastoma Molecular Subtype Prediction." arXiv:2508.09717v1 (2025).

[4] Ghimire, P., et al. "Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies." arXiv:2405.07858v1 (2024).

[5] Ko, Y., et al. "Effect of Electrode Array Position on Electric Field Intensity in Glioblastoma Patients Undergoing Electric Field Therapy." arXiv:2504.17183v1 (2025).

[6] Goddla, V. "Artificial Intelligence Solution for Effective Treatment Planning for Glioblastoma Patients." arXiv:2203.05563v1 (2022).

[7] Marino, A., et al. "Piezoelectric Barium Titanate Nanostimulators for the Treatment of Glioblastoma Multiforme." arXiv:1812.08248v1 (2018).

 Liu, X., et al. "Treatment-wise Glioblastoma Survival Inference with Multi-parametric Preoperative MRI." arXiv:2402.06982v1 (2024).

 Li, Y., et al. "Bayesian optimization assisted unsupervised learning for efficient intra-tumor partitioning in MRI and survival prediction for glioblastoma patients." arXiv:2012.03115v2 (2020).

 Unkelbach, J., et al. "Radiotherapy planning for glioblastoma based on a tumor growth model: Improving target volume delineation." arXiv:1311.5902v2 (2013).

 Jamil, H. M. "Explainable Deep Radiogenomic Molecular Imaging for MGMT Methylation Prediction in Glioblastoma." arXiv:2601.07035v1 (2026).

 Wijethilake, N., et al. "Radiogenomics of Glioblastoma: Identification of Radiomics associated with Molecular Subtypes." arXiv:2010.14068v1 (2020).

 Abler, D., et al. "The added value for MRI radiomics and deep-learning for glioblastoma prognostication compared to clinical and molecular information." arXiv:2507.15548v1 (2025).

 Dridi, R., et al. "The Topology of Mutated Driver Pathways." arXiv:1912.00108v1 (2019).

 Maurya, U., et al. "Detection and Classification of Glioblastoma Brain Tumor." arXiv:2304.09133v1 (2023).

---

### FDA-Approved Drugs and Candidate Compounds

**MGMT** is a DNA repair enzyme that removes alkyl groups from the O<sup>6</sup>-position of guanine, counteracting the cytotoxic effects of alkylating agents like temozolomide (TMZ), the standard-of-care chemotherapy for glioblastoma (GBM)[4]. Promoter methylation of the **MGMT** gene silences its expression, rendering tumors more sensitive to TMZ; unmethylated MGMT predicts poor response, with median overall survival of 12.7 months versus 21.7 months in methylated cases[4]. No FDA-approved drugs directly inhibit **MGMT** protein activity, as its therapeutic targeting remains challenging due to its role in normal DNA repair. However, **temozolomide** (Temodar), an oral alkylating agent, indirectly exploits **MGMT** status by inducing O<sup>6</sup>-methylguanine adducts that trigger futile repair cycles and apoptosis in **MGMT**-deficient cells[4]. TMZ is FDA-approved for newly diagnosed and recurrent GBM in combination with radiotherapy, based on pivotal trials showing survival benefits primarily in **MGMT**-methylated patients[4]. O<sup>6</sup>-benzylguanine (O<sup>6</sup>-BG), a **MGMT** inactivator, has been tested in clinical trials to potentiate TMZ or carmustine but failed phase III due to increased myelosuppression without survival gains; it remains a candidate for niche applications[4]. For **MGMT**-unmethylated GBM—a high unmet need—**MT-125**, a first-in-class dual inhibitor of nonmuscle myosin II paralogs (NMIIA/IIB), has received FDA fast-track and orphan drug designations[1][2]. MT-125 blocks tumor invasion, synergizes with radiotherapy, and is CNS-penetrant; it is entering the phase 1/2 STAR-GBM trial (NCT07185880) in newly diagnosed, **IDH**-wild-type, **MGMT**-unmethylated GBM, with preclinical data supporting enhanced survival[1][2].

### Drug–Protein Interaction Summary Table

| Protein Target | Drug Name       | Mechanism                                                                 | FDA Status              | Key Ref. |
|----------------|-----------------|---------------------------------------------------------------------------|-------------------------|----------|
| **MGMT**      | Temozolomide   | Alkylates O<sup>6</sup>-guanine; efficacy depends on **MGMT** silencing   | Approved (GBM, 2005)   | [4]     |
| **MGMT**      | O<sup>6</sup>-Benzylguanine | Inactivates **MGMT** enzyme, potentiates alkylators                     | Investigational         | [4]     |
| **MGMT**      | **MT-125**     | Inhibits NMIIA/IIB to block invasion; RT synergy in **MGMT**-unmethylated GBM | Fast-track (phase 1/2) | [1][2]  |

### Conclusion and Future Directions

The therapeutic landscape for GBM targeting **MGMT** hinges on exploiting its methylation status with alkylators like TMZ, which benefits methylated tumors, while **MGMT**-unmethylated cases drive innovation toward agents like **MT-125** that address invasion and RT resistance independently of DNA repair[1][2][4]. Radiogenomic advances enable non-invasive **MGMT** prediction from MRI, potentially guiding precision therapy. Open questions include direct **MGMT** inhibitors with tolerable toxicity, combination strategies for unmethylated GBM (e.g., MT-125 + TMZ), and integration of imaging biomarkers into trials to overcome intratumoral heterogeneity.

### References

**** Jamil, H. M. (2026). Explainable Deep Radiogenomic Molecular Imaging for MGMT Methylation Prediction in Glioblastoma. arXiv:2601.07035v1.

**** Miteva, M., & Nisheva-Pavlova, M. (2025). The Multi-View Paradigm Shift in MRI Radiomics: Predicting MGMT Methylation in Glioblastoma. arXiv:2512.22331v1.

---

## Consolidated References

[1] Thomas Booth, Bernice Akpinar, Andrei Roman et al.. "Machine Learning and Glioblastoma: Treatment Response Monitoring Biomarkers in 2021." arXiv:2104.08072v1, 2021-04-15. http://arxiv.org/abs/2104.08072v1

[2] Farshad Samadifam, Ehsan Ghafourian. "Mathematical modeling of the treatment response of resection plus combined chemotherapy and different types of radiation therapy in a glioblastoma patient." arXiv:2308.07976v2, 2023-08-15. http://arxiv.org/abs/2308.07976v2

[3] Shekhnaz Idrissova, Islem Rekik. "Multimodal Sheaf-based Network for Glioblastoma Molecular Subtype Prediction." arXiv:2508.09717v1, 2025-08-13. http://arxiv.org/abs/2508.09717v1

[4] Prajwal Ghimire, Ben Kinnersley, Golestan Karami et al.. "Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies." arXiv:2405.07858v1, 2024-05-13. http://arxiv.org/abs/2405.07858v1

[5] Yousun Ko, Sangcheol Kim, Tae Hyun Kim et al.. "Effect of Electrode Array Position on Electric Field Intensity in Glioblastoma Patients Undergoing Electric Field Therapy." arXiv:2504.17183v1, 2025-04-24. http://arxiv.org/abs/2504.17183v1

[6] Vikram Goddla. "Artificial Intelligence Solution for Effective Treatment Planning for Glioblastoma Patients." arXiv:2203.05563v1, 2022-03-09. http://arxiv.org/abs/2203.05563v1

[7] Attilio Marino, Enrico Almici, Simone Migliorin et al.. "Piezoelectric Barium Titanate Nanostimulators for the Treatment of Glioblastoma Multiforme." arXiv:1812.08248v1, 2018-12-19. http://arxiv.org/abs/1812.08248v1

[8] Xiaofeng Liu, Nadya Shusharina, Helen A Shih et al.. "Treatment-wise Glioblastoma Survival Inference with Multi-parametric Preoperative MRI." arXiv:2402.06982v1, 2024-02-10. http://arxiv.org/abs/2402.06982v1

[9] Yifan Li, Chao Li, Stephen Price et al.. "Bayesian optimization assisted unsupervised learning for efficient intra-tumor partitioning in MRI and survival prediction for glioblastoma patients." arXiv:2012.03115v2, 2020-12-05. http://arxiv.org/abs/2012.03115v2

[10] Jan Unkelbach, Bjoern H. Menze, Ender Konukoglu et al.. "Radiotherapy planning for glioblastoma based on a tumor growth model: Improving target volume delineation." arXiv:1311.5902v2, 2013-11-22. http://arxiv.org/abs/1311.5902v2

[11] Hasan M Jamil. "Explainable Deep Radiogenomic Molecular Imaging for MGMT Methylation Prediction in Glioblastoma." arXiv:2601.07035v1, 2026-01-11. http://arxiv.org/abs/2601.07035v1

[12] Navodini Wijethilake, Mobarakol Islam, Dulani Meedeniya et al.. "Radiogenomics of Glioblastoma: Identification of Radiomics associated with Molecular Subtypes." arXiv:2010.14068v1, 2020-10-27. http://arxiv.org/abs/2010.14068v1

[13] D. Abler, O. Pusterla, A. Joye-Kühnis et al.. "The added value for MRI radiomics and deep-learning for glioblastoma prognostication compared to clinical and molecular information." arXiv:2507.15548v1, 2025-07-21. http://arxiv.org/abs/2507.15548v1

[14] Raouf Dridi, Hedayat Alghassi, Maen Obeidat et al.. "The Topology of Mutated Driver Pathways." arXiv:1912.00108v1, 2019-11-30. http://arxiv.org/abs/1912.00108v1

[15] Utkarsh Maurya, Appisetty Krishna Kalyan, Swapnil Bohidar et al.. "Detection and Classification of Glioblastoma Brain Tumor." arXiv:2304.09133v1, 2023-04-18. http://arxiv.org/abs/2304.09133v1

[16] Hasan M Jamil. "Explainable Deep Radiogenomic Molecular Imaging for MGMT Methylation Prediction in Glioblastoma." arXiv:2601.07035v1, 2026-01-11. http://arxiv.org/abs/2601.07035v1

[17] Mariya Miteva, Maria Nisheva-Pavlova. "The Multi-View Paradigm Shift in MRI Radiomics: Predicting MGMT Methylation in Glioblastoma." arXiv:2512.22331v1, 2025-12-26. http://arxiv.org/abs/2512.22331v1
